In their Correspondence, Silvia Accordini and colleagues1 described the case of a 35-year-old man who used pre-exposure prophylaxis (PrEP) for HIV who, after a household contact with a person with mpox (formerly known as monkeypox), did not develop any skin lesion, but tested positive for MPXV and subsequently had seroconversion (indirect immunofluorescence) at 30 days follow-up.1 To support the authors speculation, we present the case of a 35-year-old man who has sex with men who uses PrEP without a previous mpox or smallpox vaccination history, whose polyamorous partner was diagnosed with mpox.
The day after the diagnosis, while completely asymptomatic, our patient underwent a full physical examination that did not detect any sign of infection. The patient was told to seek medical attention at any sign or symptom of infection in the 21 days following the last contact with their partner and to refrain from sexual activity. After 4 days, the patient returned reporting pubic pustules in absence of any other symptom. The presence of MPXV DNA was investigated on pharynx and lesion swabs by RT-PCR test. He also underwent a full sexually transmitted infections screen and HSV-1/2 DNA on lesion sample. All tests came back negative with the exception of HSV-1 DNA on lesion swab and Neisseria gonorrhoeae on anal sample; the patient was thus prescribed with oral valacyclovir and ceftriaxone, and reported full healing of the lesions. The patient did not develop any other symptoms for the whole surveillance period. After 1 month, a serological test was proposed to look for neutralising antibodies against MPXV using the in vitro plaque reduction neutralisation test. A serum sample of the patient was diluted and mixed with MPXV suspension on Vero E6 cell culture. The test was positive for mpox-virus neutralising antibodies with a titre of 1:160.
Reda and colleagues2 called for greater attention on infection control, including individuals who are asymptomatic and paucisymptomatic. Nevertheless, Van Dijck and colleagues3 underscored how unrecognised signs or unreported symptoms account for almost all the cases of what were believed to be asymptomatic infections.
Our experience, corroborated by an active surveillance and accurate physical examination, supports the findings by Accordini and colleagues1 in reinforcing the speculations that, not only individuals with atypical presentations, but also people who are completely asymptomatic might have a role in spreading and sustaining MPXV circulation, justifying the persistent sporadic occurrence of mpox cases nowadays, in a phase of apparent remission of the mpox epidemic.
We declare no competing interests.
Contributor Information
Sacco Mpox Study Group:
SPINELLO ANTINORI, MICOL BIANCHI, AMEDEO FERIDNANDO CAPETTI, FRANCESCO CARUSO, MARTINA LAURA COLOMBO, MARIA VITTORIA COSSU, MIRIAM CUTRERA, MARIA RITA GISMONDO, ANDREA GORI, SAMUEL LAZZARIN, ALESSANDRA LOMBARDI, VALERIA MICHELI, ANDREA PASTENA, GIACOMO POZZA, GIULIANO RIZZARDINI, ALBERTO RIZZO, FEDERICO SABAINI, and FEDERICA SALARI
References
- 1.Accordini S, Cordioli M, Pomari E, Tacconelli E, Castilletti C. People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission. Lancet Microbe. 2023;4:e209. doi: 10.1016/S2666-5247(22)00379-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Reda A, El-Qushayri AE, Shah J. Asymptomatic monkeypox infection: a call for greater control of infection and transmission. Lancet Microbe. 2023;4:e15–e16. doi: 10.1016/S2666-5247(22)00259-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Van Dijck C, De Baetselier I, Kenyon C, et al. Mpox screening in high-risk populations finds no asymptomatic cases. Lancet Microbe. 2023;4:e132–e133. doi: 10.1016/S2666-5247(22)00357-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
